Project: Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment

Acronym ImmuneNOVA (Reference Number: 11889)
Duration 01/04/2018
Project Topic ImmuneNOVA aims to establish preclinical proof-of-concept in in vivo oncology models and in relevant patient-derived in vitro cell models for a novel immune checkpoint inhibitor targeting CMTM6. This inhibitor blocks a known immune checkpoint axis, PD-1/PD-L1, by decreasing cell surface expression of PD-L1, and so potentiates anti-tumour immunity. This novel inhibitor can be used to treat advanced forms of cancer, such as lung cancer, skin cancer (melanoma) and kidney cancer.
Network Eurostars 2
Call Eurostars Cut-Off 8

Project partner

Number Name Role Country
1 Scenic Biotech B.V. Coordinator Netherlands
2 Adlego Biomedical AB Partner Sweden
3 Ciloa SAS Partner France
4 InSphero AG Partner Switzerland